²¹²Pb-VMT-α-NET is the therapeutic analogue of the Imaging agent ²⁰³Pb-VMT-α-NET (presently under Phase I/II clinical development) analogue of ¹⁷⁷Lu-DOTATOC. The Tracer and the associated drug, an Alpha emitter, are developed by Viewpoint Molecular Targeting for treatment of patients with neuroendocrine tumors (NET). A Phase I trial is under preparation and should be initiated during the year 2023. In January 2023, the company announced that a patient in India received a dose in the frame of compassionate use.

Target/Mechanism: somatostatin receptors

Carrier/Ligand: Peptide

Radiation Type: Alpha particle (α)